Our Mission is to Reduce Late Stage Cancer by 50% Over the Next Ten Years through Early Interventions
StageZero Life Sciences, Inc. is dedicated to the early detection of cancer and multiple disease states through whole blood. We currently offer blood-based biomarker tests for four of the most prevalent cancers (Colorectal, Lung, Prostate & Lung).
Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proprietary mRNA technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of the Aristotle test are currently underway.
You can learn more about StageZero Life Sciences at StageZeroLifeSciences.com